226 related articles for article (PubMed ID: 36430945)
1. Therapeutic Efficacy and Outcomes of Remdesivir versus Remdesivir with Tocilizumab in Severe SARS-CoV-2 Infection.
Vulturar DM; Neag MA; Vesa ȘC; Maierean AD; Gherman D; Buzoianu AD; Orăsan OH; Todea DA
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430945
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
3. Changing patterns and clinical outcomes of hospitalized patients with COVID-19 severe pneumonia treated with remdesivir according to vaccination status: results from a real-world retrospective study.
Mengato D; Mazzitelli M; Francavilla A; Bettio M; Sasset L; Presa N; Pivato L; Lo Menzo S; Trevenzoli M; Venturini F; Gregori D; Cattelan AM
Clin Exp Med; 2023 Oct; 23(6):2749-2756. PubMed ID: 36961678
[TBL] [Abstract][Full Text] [Related]
4. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
5. Factors associated with critical care requirements in diabetic patients treated with dexamethasone for COVID-19 infection in the first wave of the pandemia.
Batule S; Soldevila B; Figueredo C; Julián MT; Egea-Cortés L; Reyes-Ureña J; Casabona J; Mateu L; Paredes R; Clotet B; López R; Puig-Domingo M; Alonso N
Front Endocrinol (Lausanne); 2022; 13():1009028. PubMed ID: 36619546
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19.
Garibaldi BT; Wang K; Robinson ML; Zeger SL; Bandeen-Roche K; Wang MC; Alexander GC; Gupta A; Bollinger R; Xu Y
JAMA Netw Open; 2021 Mar; 4(3):e213071. PubMed ID: 33760094
[TBL] [Abstract][Full Text] [Related]
7. Remdesivir for the Treatment of Severe COVID-19: A Community Hospital's Experience.
Lee S; Santarelli A; Caine K; Schritter S; Dietrich T; Ashurst J
J Am Osteopath Assoc; 2020 Dec; 120(12):926-933. PubMed ID: 33136164
[TBL] [Abstract][Full Text] [Related]
8. Time from symptoms onset to remdesivir is associated with the risk of ICU admission: a multicentric analyses.
Alonso-Navarro R; Ramírez M; Masiá M; Paredes R; Montejano R; Povar-Echeverria M; Carratalà J; Salavert M; Bernal E; Dueñas C; Flores J; Fanjul F; Gutiérrez I; Rico V; Mateu L; Cadiñanos J; Berenguer J; Soriano A
BMC Infect Dis; 2023 May; 23(1):286. PubMed ID: 37142994
[TBL] [Abstract][Full Text] [Related]
9. Impact of Timing of Tocilizumab Use in Hospitalized Patients With SARS-CoV-2 Infection.
Singh AK; Oks M; Husk G; Dechario SP; Mina B; Singh K; Kirschenbaum L; Carpati CM; Mahmoud O; Gabra NI; Ishikawa O; Altschultz E; Shah V; Mahajan A; Gautam A; Birnbaum B; Antonacci AC; Raoof S
Respir Care; 2021 Dec; 66(12):1805-1814. PubMed ID: 34548407
[TBL] [Abstract][Full Text] [Related]
10. Treatment of COVID-19 pneumonia with glucocorticoids (CORTIVID): a structured summary of a study protocol for a randomised controlled trial.
Les Bujanda I; Loureiro-Amigo J; Bastons FC; Guerra IE; Sánchez JA; Murgadella-Sancho A; Rey RG; López JL; Álvarez JS
Trials; 2021 Jan; 22(1):43. PubMed ID: 33430891
[TBL] [Abstract][Full Text] [Related]
11. [Evaluation of the Effects of Tocilizumab Use on Oxygen Parameters, Inflammatory Markers and Survival in Patients Diagnosed with COVID-19 in Intensive Care Unit].
Yılmaz B; Doğan M; Ergut Sezer B
Mikrobiyol Bul; 2023 Jan; 57(1):97-107. PubMed ID: 36636849
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy with remdesivir and immunomodulators improves respiratory status in COVID-19: A retrospective study.
Kojima Y; Nakakubo S; Kamada K; Yamashita Y; Takei N; Nakamura J; Matsumoto M; Horii H; Sato K; Shima H; Suzuki M; Konno S
J Med Virol; 2022 Dec; 94(12):5702-5712. PubMed ID: 35916111
[TBL] [Abstract][Full Text] [Related]
13. Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care.
Olender SA; Perez KK; Go AS; Balani B; Price-Haywood EG; Shah NS; Wang S; Walunas TL; Swaminathan S; Slim J; Chin B; De Wit S; Ali SM; Soriano Viladomiu A; Robinson P; Gottlieb RL; Tsang TYO; Lee IH; Hu H; Haubrich RH; Chokkalingam AP; Lin L; Zhong L; Bekele BN; Mera-Giler R; Phulpin C; Edgar H; Gallant J; Diaz-Cuervo H; Smith LE; Osinusi AO; Brainard DM; Bernardino JI;
Clin Infect Dis; 2021 Dec; 73(11):e4166-e4174. PubMed ID: 32706859
[TBL] [Abstract][Full Text] [Related]
14. Patients with moderate to severe COVID-19 outcomes on remdesivir according to baseline 4C mortality score.
Sellers J; Chang J; Jones J; Hintze TD
Pulm Pharmacol Ther; 2023 Feb; 78():102188. PubMed ID: 36603741
[TBL] [Abstract][Full Text] [Related]
15. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Wang Y; Zhang D; Du G; Du R; Zhao J; Jin Y; Fu S; Gao L; Cheng Z; Lu Q; Hu Y; Luo G; Wang K; Lu Y; Li H; Wang S; Ruan S; Yang C; Mei C; Wang Y; Ding D; Wu F; Tang X; Ye X; Ye Y; Liu B; Yang J; Yin W; Wang A; Fan G; Zhou F; Liu Z; Gu X; Xu J; Shang L; Zhang Y; Cao L; Guo T; Wan Y; Qin H; Jiang Y; Jaki T; Hayden FG; Horby PW; Cao B; Wang C
Lancet; 2020 May; 395(10236):1569-1578. PubMed ID: 32423584
[TBL] [Abstract][Full Text] [Related]
16. Tocilizumab versus anakinra in COVID-19: results from propensity score matching.
Arcani R; Correard F; Suchon P; Kaplanski G; Jean R; Cauchois R; Leprince M; Arcani V; Seguier J; De Sainte Marie B; Andre B; Koubi M; Rossi P; Gayet S; Gobin N; Garrido V; Weiland J; Jouve E; Couderc AL; Villani P; Daumas A
Front Immunol; 2023; 14():1185716. PubMed ID: 37304271
[TBL] [Abstract][Full Text] [Related]
17. Use of Remdesivir in Patients Hospitalized for COVID-19 Pneumonia: Effect on the Hypoxic and Inflammatory State.
Libra A; Ciancio N; Sambataro G; Sciacca E; Muscato G; Marino A; Vancheri C; Spicuzza L
Viruses; 2023 Oct; 15(10):. PubMed ID: 37896877
[TBL] [Abstract][Full Text] [Related]
18. Remdesivir in combination with dexamethasone for patients hospitalized with COVID-19: A retrospective multicenter study.
Gressens SB; Esnault V; De Castro N; Sellier P; Sene D; Chantelot L; Hervier B; Delaugerre C; Chevret S; Molina JM;
PLoS One; 2022; 17(2):e0262564. PubMed ID: 35176057
[TBL] [Abstract][Full Text] [Related]
19. Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.
Lyngbakken MN; Berdal JE; Eskesen A; Kvale D; Olsen IC; Rangberg A; Jonassen CM; Omland T; Røsjø H; Dalgard O
Trials; 2020 Jun; 21(1):485. PubMed ID: 32503662
[TBL] [Abstract][Full Text] [Related]
20. Clinical evolution and mortality of critically ill patients with SARS-CoV-2 pneumonia treated with remdesivir in an adult intensive care unit of Paraguay.
Figueredo J; Lopez LF; Leguizamon BF; Samudio M; Pederzani M; Apelt FF; Añazco P; Caballero R; Bianco H
BMC Infect Dis; 2024 Jan; 24(1):37. PubMed ID: 38166777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
